Instructions for Authors
Annals of Clinical Trials and Vaccines Research provides the rapid publication of articles in all areas of the subject. Annals of Clinical Trials and Vaccines Research welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published approximately one month after acceptance.
Submit manuscripts online at https://www.scholarscentral.org/submissions/annals-clinical-trials-vaccines-research.html or
A manuscript number will be emailed to the corresponding author within 72 hours.
Article Processing Charges (APC) :
Publishing with open access is not without costs. Openaccess Journals defrays those costs from article-processing charges (APCs) payable by authors once the manuscript has been accepted for publication. Openaccessjournals does not have subscription charges for its research content, believing instead that immediate, world-wide, barrier-free, open access to the full text of research articles is in the best interests of the scientific community.
Average Article prorcessing time (APT) is 45 days
*50% of the publication charges will be applicable as withdrawal fees once the article is processed.
# The charges would be calculated in USD (For America, Asia, Africa, Australia), Euros (For European countries) and GBP (For United Kingdom).
The basic article processing fee or manuscript handling cost is as per the price mentioned above on the other hand it may vary based on the extensive editing, colored effects, complex equations, extra elongation of no. of pages of the article, etc.
Fast Editorial Execution and Review Process (FEE-Review Process):
Annals of Clinical Trials and Vaccines Research is participating in the Fast Editorial Execution and Review Process (FEE-Review Process) with an additional prepayment of $99 apart from the regular article processing fee. Fast Editorial Execution and Review Process is a special service for the article that enables it to get a faster response in the pre-review stage from the handling editor as well as a review from the reviewer. An author can get a faster response of pre-review maximum in 3 days since submission, and a review process by the reviewer maximum in 5 days, followed by revision/publication in 2 days. If the article gets notified for revision by the handling editor, then it will take another 5 days for external review by the previous reviewer or alternative reviewer.
Acceptance of manuscripts is driven entirely by handling editorial team considerations and independent peer-review, ensuring the highest standards are maintained no matter the route to regular peer-reviewed publication or a fast editorial review process. The handling editor and the article contributor are responsible for adhering to scientific standards. The article FEE-Review process of $99 will not be refunded even if the article is rejected or withdrawn for publication.
The corresponding author or institution/organization is responsible for making the manuscript FEE-Review Process payment. The additional FEE-Review Process payment covers the fast review processing and quick editorial decisions, and regular article publication covers the preparation in various formats for online publication, securing full-text inclusion in a number of permanent archives like HTML, XML, and PDF, and feeding to different indexing agencies.
Submission of an Article
In order to reduce delays, authors should adhere to the level, length and format of the Annals of Clinical Trials and Vaccines Research Journal at every stage of processing right from manuscript submission to each revision stage. Submitted articles should have a 300 words summary/abstract, separate from the main text. The summary should provide a brief account of the work by clearly stating the purpose of the study and the methodology adopted, highlighting major findings briefly. The text may contain a few short subheadings of no more than 40 characters each.
Formats for Annals of Clinical Trials and Vaccines Research Journal contributions
Annals of Clinical Trials and Vaccines Research accepts various formats of literary works such as research articles, reviews, abstracts, addendums, announcements, article-commentaries, book reviews, rapid communications, letters to the editor, annual meeting abstracts, conference proceedings, calendars, case-reports, corrections, discussions, meeting-reports, news, obituaries, orations, product reviews, hypotheses and analyses. Article Preparation Guidelines: • Authors are expected to attach an electronic covering letter completely mentioning the type of manuscript (e.g, Research article, Review articles, Brief Reports, Case study etc.) Unless invited on a special case, authors cannot classify a particular manuscript as Editorials or Letters to the editor or concise communications. • Confirm that each individual named as an author meets the uniform requirements of the Journal of Annals of Clinical Trials and Vaccines Research criteria for authorship. • Please make sure that the article submitted for review/publication is not under consideration elsewhere simultaneously. • Clearly mention financial support or benefits if any from commercial sources for the work reported in the manuscript, or any other financial interests that any of the authors may have, which could create a potential conflict of interest or the appearance of a conflict of interest with regard to the work. • A clear title of the article along with complete details of the author/s (professional/institutional affiliation, educational qualifications and contact information) must be provided in the tile page. • Corresponding author should include address, telephone number, fax number, and e-mail address in the first page of the manuscript and authors must address any conflict of interest with others once the article is published. • Number all sheets in succession, including references, tables, and figure legends. • Title page is page 1. On the first page, type the running head (short title for top of each page), title (which cannot include any acronyms), names of the authors and their academic degrees, grants or other financial supporters of the study, address for correspondence and reprint requests, and corresponding author's telephone and fax numbers and e-mail address.
Guidelines for Research Articles
Research articles are articles written based on the empirical/secondary data collected using a clearly defined research methodology, where conclusion/s is drawn from the analysis of the data collected. The information must be based on original research that adds to the body of knowledge in Annals of Clinical Trials and Vaccines Research. Article/s should provide a critical description or analysis of the data presented while adding new and rapidly evolving areas in the field. Include an abstract of maximum 300 words with 7 to 10 important keywords. The abstract should be divided into Objective, Methods, Results, and Conclusion. Research articles must adhere to a format constituting the introduction followed by a brief review of relevant literature, methodology applied (to collect the data), discussion and References, Tables, and Figure Legends.
Review articles are written based mostly on secondary data that is falling in line with the theme of the journal. They are brief, yet critical discussions on a specific aspect of the subject concerned. Reviews generally start with the statement of the problem with a brief abstract of 300 words and few key words. Introduction generally brings the issue forward to the readers followed by analytical discussion with the help of necessary tables, graphs, pictures and illustrations wherever necessary. It summarizes the topic with a conclusion. All the statements or observations in the review articles must be based on necessary citations, providing complete reference at the end of the article.
Commentaries are opinion articles written mostly by the veteran and experienced writers on a specific development, recent innovation or research findings that fall in line with the theme of the journal. They are very brief articles with the title and abstract that provides the gist of the topic to be discussed, with few key words. It straight away states the problems and provides a thorough analysis with the help of the illustrations, graphs and tables if necessary. It summarizes the topic with a brief conclusion, citing the references at the end.
Case studies are accepted with a view to add additional information related to the investigative research that advances in the field of Annals of Clinical Trials and Vaccines Research. It should add value to the main content/article submitted, by providing key insights about the core area. Cases reports must be brief and follow a clear format such as Cases and Methods Section (That describe the nature of the clinical issue and the methodology adopt to address it), discussion section that analyzes the case and a Conclusion section that sums up the entire case.
Editorials are concise commentaries on a currently published article/issue on Annals of Clinical Trials and Vaccines Research. Editorial office may approach for any such works and authors must submit it within three weeks from the date of receiving invitation.
Clinical Images are nothing but photographic depictions of Annals of Clinical Trials and Vaccines Research and it should not exceed more than 5 figures with a description, not exceeding 300 words. Generally no references and citations are required here. If necessary, only three references can be allowed. Do not add separate figure legends to clinical images; the entire clinical image text is the figure legend. Images should be submitted with the manuscript in one of the following formats: .tiff (preferred) or .eps.
Letters to the Editor/Concise Communications
Letters to the editor should be limited to commentaries on previous articles published with specific reference to issues and causes related to it. It should be concise, comprehensive and brief reports of cases or research findings. It does not follow a format such as abstract, subheads, or acknowledgments. It is more a response or the opinion of the reader on a particular article published and should reach the editor within 6 months of article publication.
Acknowledgement: This section includes acknowledgment of people, grant details, funds, etc.
Note: If an author fails to submit his/her work as per the above instructions, they are pleased to maintain clear titles namely headings, subheadings and respective subtitles.
Only published or accepted manuscripts should be included in the reference list. Meetings abstracts, conference talks, or papers that have been submitted but not yet accepted should not be cited. All personal communications should be supported by a letter from the relevant authors. Supplementary Information (for example, figures, tables) referred to an appropriate point in the main text of the paper. Summary diagram/figure included as part of the Supplementary Information (optional). All the Supplementary Information must be supplied as a single PDF file and file size should be within the permitted limits. Images should be maximum of 640 x 480 pixels (9 x 6.8 inches at 72 pixels per inch) in size.
Annals of Clinical Trials and Vaccines Research Policy Regarding the NIH Mandate
Annals of Clinical Trials and Vaccines Research will support authors by posting the published version of articles by NIH grant-holders to PubMed Central immediately after publication. Proofs and Reprints: Electronic proofs will be sent as an e-mail attachment to the corresponding author as a PDF file. Page proofs are considered to be the final version of the manuscript. With the exception of typographical or minor clerical errors, no changes will be made in the manuscript at the proof stage. Authors will have free electronic access to the full text (HTML, PDF and XML) of the article. Benefits: Benefits of Open Access include greater visibility, accelerated citation, immediate access to the full text versions, higher impact and authors retain the copyright to their work. All open access articles are published under the terms of the Creative Commons Attribution (CC-BY) license. It also allows immediate deposit of the final published version in other repositories without restriction on re-use. Copy Rights: Authors opted for subscription mode must sign copyright transfer agreement prior to publication of their article. Publisher reserves the copyright and any extensions or renewals of that term thereof throughout the world, including but not limited to publish, disseminate, transmit, store, translate, distribute, sell, republish and use the contribution and material contained therein in print and electronic form of the journal and in other derivative works, in all languages and any form of media of expression available now or in the future and to license or permit others to do so Copyright © 2016 Open Access Journals. All Rights Reserved.